Sangamo Biosciences (SGMO) Misses Q2 EPS by 14c

Sangamo Biosciences (NASDAQ: SGMO) reported Q2 EPS of ($0.38), $0.14 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $5.38 million.

Financial Guidance for 2016 The Company updates guidance as follows:

• Cash and Investments: Sangamo expects that its cash, cash equivalents and marketable securities will be at least $140 million at the end of 2016, inclusive of research funding from existing collaborators but exclusive of funds arising from any additional new collaborations or partnerships, equity financings or other new sources.
• Revenues: Sangamo expects that revenues will be in the range of $12 million to $17 million in 2016, inclusive of research funding from existing collaborations.
• For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c